Article
A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes.
Endocrine journal - 1 Jan 2009
Makino Hideichi, Shimizu Ikki, Murao Satoshi, Kondo Shiori, Tabara Yasuharu, Fujiyama Masao, Fujii Yasuhisa, Takada Yasuharu, Nakai Kazuaki, Izumi Kenichi, Ohashi Jun, Kawamura Ryoichi, Yamauchi Junko, Takata Yasunori, Nishida Wataru, Hashiramoto Mitsuru, Onuma Hiroshi, Osawa Haruhiko
Abstract excerpt
The aim of this study was to determine the relation between the G/G genotype of a resistin gene promoter single nucleotide polymorphism (SNP) at -420 (rs1862513) and glycemic control by pioglitazone in type 2 diabetes. In Study 1, 121 type 2 diabetic patients were treated with pioglitazone (15 or 30 mg/day) for 12 weeks, in addition to previous medication. In Study 2, 63 patients who had been treated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.